Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?

Merck, a roughly $70 billion-revenue pharmaceutical giant, faces concentration risk with nearly half its sales from oncology franchise Keytruda whose patent protection begins expiring in 2028, but recent developments — approval of subcutaneous Keytruda Qlex, positive phase 3 data for Winrevair and acquisitions (Verona Pharma closed; $9B Cidara deal announced) — underpin a bullish view. Management projects the pipeline could generate more than $50 billion annually by the mid-2030s while analysts expect Winrevair to grow from ~ $1B in 2025 toward ~$8B in coming years. Shares trade at under 12x next year’s projected EPS with a ~3.3% forward dividend yield, and the market’s recent 30% rebound since September reflects renewed investor confidence despite the patent cliff risk.

Analysis

Market structure: Merck (MRK) benefits directly from Keytruda Qlex, Winrevair momentum and tuck‑ins (Verona, Cidara) while biosimilar makers and PD‑1 price competitors stand to gain share as Keytruda loses exclusivity in 2028. Expect PD‑1 pricing pressure when biosimilars launch (typical ASP declines 30–60%), but near‑term demand remains strong across oncology and pulmonary niches, supporting mid‑teens revenue growth in adjacent franchises. Credit markets should treat MRK as defensive — small impact on IG spreads but equity implied vol likely to compress as fear of cliff recedes.

Risk assessment: Tail risks include accelerated biosimilar entry via adverse litigation/FDA rulings, failed late‑stage readouts (Winrevair/other assets) or integration setbacks that could cost $5–10B revenue and compress EPS >20%. Immediate (days) risk centers on quarterly guidance and FDA/regulatory headlines; short term (3–12 months) on Qlex uptake and Winrevair 2025 sales trajectory; long term (2026–2035) on whether pipeline can scale toward management’s $50B run‑rate claim. Hidden dependencies: payer formulary decisions, hospital infusion economics, and international pricing negotiations can rapidly change realized price/per patient.

Trade implications: Tactical: establish a 2–3% portfolio long in MRK at <$105 targeting $115–$135 (15–30%) over 12–18 months with a 15% stop‑loss (~$90) or buy a protective 2025 Jan 90 put. Income: if long MRK, sell covered calls (Jan 2026 120 C) to harvest premium and lower basis. Pair: long MRK vs short BMY (size ratio 1:0.8) to express MRK’s Qlex/portfolio optionality versus Opdivo competitor; trim if MRK/BMY ratio >+10%.

Contrarian angles: The market has likely over‑priced a total revenue cliff — MRK trades <12x FY1 EPS while peers trade 15–18x, underestimating cumulative pipeline and M&A offset (possible $30–50B mid‑2030s upside). Reaction may be underdone if pipeline starts converting to revenue; conversely, if Qlex uptake stalls (<10% PD‑1 share in 12 months) or biosimilars capture >25% market in first year post‑expiry, downside could be sharp. Valuation trigger to sell/trim: MRK >15x forward EPS or price >$130 absent commensurate pipeline proof points.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in MRK at current levels (<= $105); target $115–$135 in 12–18 months (15–30% upside). Implement a hard stop‑loss at ~15% ($~90) or hedge by buying MRK Jan 2025 90 puts if downside protection is required.
• If long MRK, sell covered calls to enhance yield: sell Jan 2026 MRK 120 calls (collect premium to reduce basis); roll or close if MRK >120 or buyback premium >50% of initial value.
• Execute a pair trade: long MRK (2% portfolio) and short BMY (1.6% portfolio) to express relative upside from Qlex and M&A; rebalance or unwind if MRK/BMY price ratio moves >±10% or if MRK forward EPS re‑rated above 15x.
• Event triggers to act: within next 90 days, if quarterly Keytruda/Qlex combined guidance misses by >3% or analyst FY26 EPS cuts exceed 5%, reduce MRK exposure by 50%. Conversely, if Winrevair 2025 sales guidance accelerates to >$2B or management confirms pipeline contributing >$10B incremental run‑rate by 2027, increase MRK to 4–5%.